Sotatercept for treating pulmonary arterial hypertension [ID6163]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 October 2025
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
10395 - Aprocitentan for treating resistant hypertension TS ID 10395Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC